Skip to main content
. 2021 Dec 1;12:725700. doi: 10.3389/fneur.2021.725700

Figure 3.

Figure 3

Efficacy of immunotherapies in refractory myasthenia gravis based on the achievement proportion of minimal manifestations (MM) (Myasthenia Gravis Foundation of America post intervention status). A random-effect model was used for quantitative synthesis. No significant difference between the MM rate of rituximab and eculizumab was found.